Abstract
Eighteen elderly patients aged 76 years or older with small cell lung cancer were treated with carboplatin (AUC = 4 mg/ml.min, i.v. day 1) and etoposide (70 mg/m2 i.v. day 1-3) and 17 patients were evaluable. The median age of the study population was 77 years (range: 76-81). Eight patients had limited disease (LD) and nine did extensive disease (ED). The overall response rate was 88% for LD patients and 67% for ED patients. Median survival time was 219 days for LD patients and 158 days for ED patients. Grade 3 and 4 leukopenia, neutropenia, thrombocytopenia and anemia occurred in 41%, 76%, 24% and 6% of patients, respectively. There was one treatment-related death due to pneumonitis.
| Original language | English |
|---|---|
| Pages (from-to) | 751-756 |
| Number of pages | 6 |
| Journal | Gan to kagaku ryoho. Cancer & chemotherapy |
| Volume | 29 |
| Issue number | 5 |
| Publication status | Published - May 2002 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- General Medicine
Fingerprint
Dive into the research topics of 'Combination chemotherapy with carboplatin and etoposide for elderly patients aged 76 years or older with small cell lung cancer'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS